Nombre del producto:Benzyl 4-chlorophenyl ketone

IUPAC Name:1-(4-chlorophenyl)-2-phenylethan-1-one

CAS:1889-71-0
Fórmula molecular:C14H11ClO
Pureza:95%+
Número de catálogo:CM250768
Peso molecular:230.69

Unidad de embalaje Stock disponible Precio($) Cantidad
CM250768-100g in stock Źŗʼn
CM250768-500g in stock ǵůŹ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :1889-71-0
Fórmula molecular:C14H11ClO
Punto de fusión:-
Código de sonrisas:ClC1=CC=C(C=C1)C(=O)CC1=CC=CC=C1
Densidad:
Número de catálogo:CM250768
Peso molecular:230.69
Punto de ebullición:365.4°C at 760 mmHg
Nº Mdl:MFCD00016342
Almacenamiento:Store at room temperature.

Column Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Monlunabant
Obesity is linked to overactivity of the endocannabinoid system that regulates appetite, fat storage, and insulin resistance. Cannabinoid receptor type-1 (CB1) belongs to the G protein-coupled receptor (GPCR) superfamily, and are found in the brain and peripheral tissues. Pharmacological blockers of CB1 receptors have demonstrated effectiveness in suppressing appetite, inducing weight loss, enhancing energy expenditure and speeding up metabolism.
Novo Nordisk’s Monlunabant is a novel peripherally-acting CB1 receptor blocker. This target limits brain penetration and minimizes psychiatric side-effects. Monlunabant is developed for the treatment of metabolic disorders. The phase 2 trials for diabetic kidney disease and obesity is expected in the second half of 2024.

Related Products